Danaher Co. (NYSE:DHR) Stake Raised by FFT Wealth Management LLC

FFT Wealth Management LLC increased its holdings in Danaher Co. (NYSE:DHR) by 52.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,214 shares of the conglomerate’s stock after acquiring an additional 760 shares during the period. FFT Wealth Management LLC’s holdings in Danaher were worth $553,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. LGL Partners LLC purchased a new stake in Danaher in the 2nd quarter worth about $247,000. Natixis Advisors LLC increased its position in Danaher by 0.5% in the 2nd quarter. Natixis Advisors LLC now owns 763,400 shares of the conglomerate’s stock worth $190,735,000 after purchasing an additional 3,607 shares during the last quarter. Equitable Trust Co. increased its position in Danaher by 9.3% in the 2nd quarter. Equitable Trust Co. now owns 10,798 shares of the conglomerate’s stock worth $2,698,000 after purchasing an additional 918 shares during the last quarter. Telos Capital Management Inc. increased its position in Danaher by 0.8% in the 2nd quarter. Telos Capital Management Inc. now owns 44,811 shares of the conglomerate’s stock worth $11,196,000 after purchasing an additional 350 shares during the last quarter. Finally, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH increased its position in Danaher by 24.5% in the 2nd quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 823 shares of the conglomerate’s stock worth $206,000 after purchasing an additional 162 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Barclays increased their price objective on Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a report on Wednesday, July 24th. Evercore ISI lowered their price objective on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Jefferies Financial Group assumed coverage on Danaher in a report on Monday, June 3rd. They set a “buy” rating and a $295.00 price objective on the stock. TD Cowen increased their price objective on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Finally, Bank of America raised their target price on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average price target of $278.94.

Insider Buying and Selling

In related news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock worth $11,042,433 in the last 90 days. 11.10% of the stock is owned by company insiders.

Danaher Price Performance

Shares of DHR stock opened at $269.31 on Monday. The stock has a 50 day moving average of $260.05 and a two-hundred day moving average of $255.24. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $281.70. The company has a market capitalization of $194.50 billion, a P/E ratio of 45.65, a P/E/G ratio of 4.43 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s revenue was down 2.9% on a year-over-year basis. During the same quarter last year, the company earned $2.05 EPS. As a group, equities analysts expect that Danaher Co. will post 7.59 EPS for the current year.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.